Benten Biotech

Executive Summary

Benten Biotech is a preclinical Brazilian biopharmaceutical company developing innovative therapeutics and diagnostics for oncology and infectious diseases. Founded in 2012 and headquartered in São Paulo, the company has raised $4 million to advance its pipeline. Despite limited public disclosure, Benten Biotech focuses on addressing high unmet medical needs in Latin America, leveraging local expertise and potential partnerships. Its lead programs remain in early research stages, with no disclosed clinical candidates. The company's success hinges on advancing its most mature asset toward IND-enabling studies and securing additional financing. Given the preclinical stage, risk is elevated, but the dual focus on oncology and infectious diseases offers diversification. Upcoming catalysts include preclinical data releases and potential funding rounds.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data for lead oncology candidate60% success
• Q4 2026Series A financing round50% success
• TBDPartnership or licensing deal for infectious disease diagnostic40% success